Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

Slides:

Advertisements

Similar presentations

The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options Sanjiv Kaul, MD Journal of Cardiology Volume 64, Issue.

Advertisements

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population Sharmini Selvarajah, Gurpreet.

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

A study on serum concentrations of oxidized low-density lipoprotein β2-glycoprotein I complex in patients with normal and dyslipidemic lipid profiles

M. Yldau van der Ende, Minke H. T. Hartman, Yanick Hagemeijer, Laura M

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Volume 93, Issue 6, Pages (June 2018)

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

My Approach to the Patient With Familial Hypercholesterolemia

Approach to the true resistant hypertensive and treatment approaches

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Jacques Genest, MD, Robert A

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

M. Yldau van der Ende, Minke H. T. Hartman, Yanick Hagemeijer, Laura M

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

Meredith Kilgore, PhD, Paul Muntner, PhD, J

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Kirolos A. Jacob, Marc P. Buijsrogge, Jos F. Frencken, Maarten J

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Volume 26, Issue 2, Pages (February 2018)

Lip edema Journal of the American Academy of Dermatology

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Simplified Canadian Definition for Familial Hypercholesterolemia

Abnormal heart-rate response during cardiopulmonary exercise testing identifies cardiac dysfunction in symptomatic patients with non-obstructive coronary.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population Sharmini Selvarajah, Gurpreet.

Atrial fibrillation: Improvement in identification and stroke preventive therapy —Data from the UK Clinical Practice Research Datalink, 2000–2012 A.C.E.

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

A review of the current guidelines for allergic rhinitis and asthma

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Support Your Specialty

International Journal of Cardiology

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department J.M. Poldervaart,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Disposition of Patients in the Atherogenic Dyslipidemia Study

Rhanderson Cardoso, MD, Roger S

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

III. Treating dyslipidemias

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation Finlay A. McAlister,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

International Journal of Cardiology

Prospective randomized study evaluating an absorbable cyanoacrylate for use in vascular reconstructions Alan B. Lumsden, MD, Eugene R. Heyman, PhD Journal.

Presentation transcript:

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour, Jean Bergeron, Daniel Gaudet, Robert Weiss, G. Kees Hovingh, Zhizhi Qing, Feng Yang, Matthew Andisik, Albert Torri, Robert Pordy, Daniel A. Gipe International Journal of Cardiology Volume 228, Pages 754-760 (February 2017) DOI: 10.1016/j.ijcard.2016.11.046 Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

Fig. 1 Patient disposition. AE, adverse event, HeFH, heterozygous familial hypercholesterolemia, OLT, open-label treatment, Q2W, every 2weeks, Q4W, every 4weeks. International Journal of Cardiology 2017 228, 754-760DOI: (10.1016/j.ijcard.2016.11.046) Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

Fig. 2 Absolute LDL-C levels over time and achievement of (A) risk-based LDL-C goals and (B) LDL-C percentage change from baseline. International Journal of Cardiology 2017 228, 754-760DOI: (10.1016/j.ijcard.2016.11.046) Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions

Fig. 3 Levels of other lipids and lipoproteins over time: (A) apo B, (B) non-HDL-C, (C) Lp(a), (D) HDL-C, and (E) triglycerides. Values shown on the charts are rounded to one decimal place. International Journal of Cardiology 2017 228, 754-760DOI: (10.1016/j.ijcard.2016.11.046) Copyright © 2016 Swiss Tropical and Public Health Institute Terms and Conditions